Icade (CDMGF) Q2 2025 Earnings Call Transcript

Icade reported resilient H1 2025 net current cash flow from strategic activities at EUR 1.44 per share, despite a 6% decline in NTA NAV to EUR 56.6 per share and an increased loan-to-value (LTV) of 38.1% reflecting asset revaluation. The company demonstrated strong operational performance with 80,000 square meters signed or renewed, improving office and light industrial occupancy, and completed over EUR 100 million in non-strategic asset disposals at NAV. Amidst a complex real estate market, Icade strengthened its liquidity with a EUR 500 million green bond, advanced portfolio diversification into student housing and urban development, and confirmed its full-year net current cash flow guidance of EUR 3.40-EUR 3.60 per share, anticipating a broader market recovery in 2027.

Analysis

Icade's H1 2025 results demonstrate operational resilience amidst a challenging real estate market, contrasted by deteriorating valuation and balance sheet metrics. The company reported a stable net current cash flow from strategic activities at €1.44 per share, down slightly from €1.47 in H1 2024, and reaffirmed its full-year guidance of €3.40-€3.60 per share. Operationally, Icade executed strong leasing activity, signing or renewing nearly 80,000 square meters, which helped improve occupancy rates for its office (88.8%) and light industrial (89.5%) portfolios. However, this was offset by significant headwinds, including a 6% decline in NTA NAV to €56.6 per share, driven by a 2.8% like-for-like drop in portfolio value. The loan-to-value (LTV) ratio increased to 38.1% from 36.5%, reflecting both this devaluation and a limited volume of disposals. While the company successfully secured over €100 million in asset sales at NAV and strengthened its liquidity with a €500 million green bond, the core Property Investment division saw gross rental income fall 4.3% like-for-like. The planned divestment of its healthcare assets is progressing slowly, with management extending a call option to Praemia and signaling a pragmatic willingness to accept a discount to NAV for a large, timely transaction, introducing uncertainty over future proceeds. Management's cautious outlook points to a full recovery being more likely in 2027, pending the success of its diversification into student housing and long-term development projects.

Key Decisions for Investors

• Investors should closely monitor the rising loan-to-value ratio of 38.1% and track the progress of asset disposals, as the company's ability to return to its sub-35% LTV target depends heavily on the successful and timely execution of its divestment plan, particularly of the healthcare portfolio.
• The reaffirmed 2025 cash flow guidance offers near-term support, but management's projection of a full recovery in 2027 suggests investors should be prepared for a multi-year transition period with continued pressure on earnings from strategic operations.
• Consider the divergence between strong operational performance, evidenced by robust leasing activity, and the negative pressure on asset valuations and rental income, which remains a primary drag on NTA NAV.
• The slow progress on the Icade Santé sale is a key variable; a potential sale at a discount to NAV could negatively impact valuation, while a successful transaction at or near NAV would serve as a positive catalyst for deleveraging.